Crescendo Biologics Further Strengthens Leadership Team With Appointment of Dr Michael Booth as Chief Financial Officer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
BridGene Biosciences Announces $12 Million Series A Financing to Advance the Company s Proprietary Chemoproteomic Platform and Pipeline of Oncology Programs
News provided by
Share this article
Share this article
SUNNYVALE, Calif., May 5, 2021 /PRNewswire/ BridGene Biosciences, Inc., a biotechnology company using cutting-edge chemoproteomic technology to discover and develop small molecules for high value, yet traditionally undruggable targets, announced today it has raised $12 million in a Series A private financing round led by Wedo Venture Partners with additional participation by Kaitai Capital and Takeda Ventures, alongside existing investor Pangu Venture.
BridGene plans to use proceeds from the Series A financing to expand the company s proprietary covalent library to discover small-molecule ligands for a broader range of targets, advance existing oncology programs and enhance operations.
Published: May 05, 2021 By Mark Terry
There’s money on the move and venture capital firms launch several biotech companies with hefty Series A financing rounds. Here’s a look.
Esker Launches with $70 Million Series A
San Francisco-based Esker Therapeutics, a Foresite Labs-incubated company,
launched with a $70 million Series A financing. The round was led by Foresite Capital. The company focuses on autoimmune diseases and so-called precision therapies that target patients most likely to benefit from them.
The company’s precision analytics platform is powered by Foresite Labs. The technology platform is made up of high-quality curated genetic, clinical and medical record data, a systems immunology approach for prospective data collections and tools for building patient registries. Its lead pipeline product is ESK-001, a highly selective TYK2 inhibitor with greater selectivity for TYK2 over JAK1, initially in development for psoriasis. It is currently in a Phase
4BIO Capital Co-leads $10 Million Seed Financing in Code Biotherapeutics
04/20/2021 | 09:00am EDT
Send by mail :
Message :
20 April 2021
LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, today announces that it has co-led a $10 million Seed financing round in Code Biotherapeutics, Inc. (“Code Bio” or the ”Company”), a next generation gene therapy company pioneering the development of targeted non-viral gene therapies for rare and prevalent genetic diseases. 4BIO actively participated in the start-up process and co-led the financing alongside UPMC Enterprises, with participation from CureDuchenne Ventures, The JDRF T1D Fund, New Enterprise Associates, and Takeda Ventures, Inc.
4Bio Capital: 4BIO Capital Co-leads $10 Million Seed Financing in Code Biotherapeutics
20 April 2021
LONDON & BOSTON - 4BIO Capital ( 4BIO or the Group ), an international venture capital firm focused solely on the advanced therapies sector, today announces that it has co-led a $10 million Seed financing round in Code Biotherapeutics, Inc. ( Code Bio or the Company ), a next generation gene therapy company pioneering the development of targeted non-viral gene therapies for rare and prevalent genetic diseases. 4BIO actively participated in the start-up process and co-led the financing alongside UPMC Enterprises, with participation from CureDuchenne Ventures, The JDRF T1D Fund, New Enterprise Associates, and Takeda Ventures, Inc.